- Neoadjuvant chemotherapy (NACT) was not associated with more complications, biliary fistula, posthepatectomy liver failure, or increased mortality in patients undergoing resection for colorectal cancer (CRC) liver metastases.
Why this matters
- NACT is known to have hepatotoxic effects, but previous studies showed mixed results as to whether postoperative morbidity/mortality is affected. The authors used propensity score matching to address the question.
- Retrospective, propensity-score matched analysis of 2832 patients (50% receiving NACT) from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Targeted Hepatectomy database.
- Funding: None disclosed.
- The NACT and non-NACT groups had similar rates (P>.05) of overall 30-day morbidity (34% vs 33%), mortality (0.8% vs 0.7%), bile leak (6% vs 5%), posthepatectomy liver failure (5% vs 5%), and posthepatectomy intervention (8% vs 8%).
- In a multivariate analysis, NACT was not associated with increased risk for postoperative complications (OR, 1.07; P=.43) or postoperative mortality (OR, 1.09; P=.85).
- There was no difference in morbidity or mortality associated with NACT in patients undergoing a right hepatectomy or trisegmentectomy (n=649).
- Retrospective analysis.